


Tapotoclax

Cat. No.:	HY-101565		
CAS No.:	1883727-34-1		
Molecular Formula:	C ₃₃ H ₄₁ ClN ₂ O ₅ S		
Molecular Weight:	613.21		
Target:	Bcl-2 Family		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (101.92 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.6308 mL	8.1538 mL	16.3076 mL
		5 mM	0.3262 mL	1.6308 mL	3.2615 mL
10 mM		0.1631 mL	0.8154 mL	1.6308 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2 mg/mL (3.26 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2 mg/mL (3.26 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2 mg/mL (3.26 mM); Suspended solution; Need ultrasonic 				

BIOLOGICAL ACTIVITY

Description	Tapotoclax (AMG-176) is a potent, selective and orally active MCL-1 inhibitor, with a K _i of 0.13 nM ^{[1][2]} .
IC₅₀ & Target	Mcl-1 0.13 nM (K _i)
In Vitro	Tapotoclax is an inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (K _i =0.13 nM), with potential pro-apoptotic and antineoplastic activities. Upon administration, Tapotoclax binds to and inhibits the activity of MCL-1. This

disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells^{[1][2]}. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Int J Cancer. 2020 Oct 15;147(8):2176-2189.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Caenepeel S, et al. AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies. Cancer Discov. 2018 Sep 25. pii: CD-18-0387.

[2]. Garner TP, et al. Progress in targeting the BCL-2 family of proteins. Curr Opin Chem Biol. 2017 Aug;39:133-142.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA